CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026, to review the company’s fourth quarter and full year 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the investors sec ...

AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Department of Justice Fraud Section (DOJ) has closed its inquiry into the Company regarding allegations of research misconduct as described in the indictment in United States v. Wang, 8: ...

MediWound to Report Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Scheduled for Thursday, March 5th at 8:30 a.m. Eastern Time YAVNE, Israel, February 19, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 5, 2026. Following the release, MediWound’s management will host a con ...

Core Insights - NorthStrive Biosciences, Inc. has filed ten new U.S. patent applications to expand its proprietary EL-22 and EL-32 technologies into animal health and agricultural markets, focusing on muscle growth and weight return in animals [1][2]. Group 1: Patent Applications Overview - The ten patent applications consist of five covering EL-22 and five covering EL-32, applicable across various farmed animal categories including livestock, aquaculture, and poultry [2]. - Two applications specifically address the use of EL-22 and EL-32 as non-feed additive supplements to promote muscle tissue growth and increase muscle weight return per animal [3]. Group 2: Environmental and Health Benefits - Additional applications aim to utilize EL-22 and EL-32 for reducing gaseous emissions in livestock, which could lower environmental impact and mitigate risks associated with ruminal tympany [4]. - In aquaculture, applications have been filed to promote muscle growth in aquatic species, potentially reducing the time to reach commercially viable sizes and lowering energy costs [5]. - Further aquaculture applications focus on emissions reduction to help mitigate eutrophic conditions [6]. Group 3: Poultry Applications - The final set of applications pertains to the use of EL-22 and EL-32 in poultry, aimed at enhancing muscle growth and improving muscle yield per bird within standard growth timelines [7]. Company Background - NorthStrive Biosciences Inc. is a biopharmaceutical company under PMGC Holdings Inc., concentrating on developing advanced aesthetic medicines, with its lead asset, EL-22, designed to address muscle preservation during weight loss treatments [8].

Investment Strategy - The preferred investment strategy is GARP (Growth At a Reasonable Price), particularly focused on stocks, with a significant emphasis on IT hardware and software sectors [1] - The investment style is described as "Fundamental Options," combining fundamental analysis with options trading to assess individual stocks and ETFs [1] Investment Focus - The investment approach includes various strategies such as income-oriented investments in BDCs and utilities, growth investments in technology, deep value based on discounted cash flow, and investments in Dividend Aristocrats [1] - The analyst typically invests for the long term but also employs 20-25 options strategies for purposes like hedging, bullish substitutes, neutral trades, trading volatility, and earnings-related trades [1] Educational Engagement - There is a passion for teaching, with experience in formal and informal education, including authoring a free local investing newsletter [1]

Definium Therapeutics, Inc. (NASDAQ:DFTX) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. Jefferies Assigns 65–75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.'s (DFTX) DT120 in Phase III The third stock on our list of most promising stocks is Definium Therapeutics, Inc. (NASDAQ:DFTX). TheFly reported on January 30 that Jefferies initiated coverage of DFTX with a Buy rating and a $30 price target. The firm highlighted that a single dose of DT120, which ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares ("ADSs†) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre- funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999. ...

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, Jefferies lowered its price target on Apogee Therapeutics Inc. (NASDAQ:APGE) to $95 from $98 while keeping its Buy rating on the stock. The analyst also reduced its risk-adjusted peak sales forecast for Apogee’s ’279 combination therapy from $1.8 billion to $1.6 billion to reflect potential limitations in high-risk patients. Jefferies’ price target adjustment on Apogee Therapeutics I ...

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 hot stocks to buy with the highest upside potential. On February 9, Sami Corwin from William Blair maintained a Buy rating on Beam Therapeutics. This maintained rating reinforced the bullish outlook that the analyst previously gave on Beam Therapeutics Inc. (NASDAQ:BEAM) in a January 21 note. Corwin noted that the existing clinical data on the lead program of Beam Therapeutics Inc. (NASDAQ:BEAM), the BEAM-302 treatment for alpha-1 antitrypsin deficiency, ...

Amicus Therapeutics Inc. (NASDAQ:FOLD) is one of the 13 hot stocks to buy with the highest upside potential. On January 27, TD Cowen analyst Ritu Baral maintained the firm’s Hold rating on Amicus Therapeutics Inc. (NASDAQ:FOLD), as well as the $14.50 price target on the stock. Amicus’s pre-announced fourth-quarter and full-year 2025 total product revenue were modestly above expectations, according to TD Cowen, with Fabry disease medication Galafold delivering a clear outperformance versus consensus estimate ...